SciGenom Labs Pvt Ltd, Kakkanad, Cochin, Kerala, India.
BMC Genomics. 2012 Aug 31;13:440. doi: 10.1186/1471-2164-13-440.
With over 1.3 billion people, India is estimated to contain three times more genetic diversity than does Europe. Next-generation sequencing technologies have facilitated the understanding of diversity by enabling whole genome sequencing at greater speed and lower cost. While genomes from people of European and Asian descent have been sequenced, only recently has a single male genome from the Indian subcontinent been published at sufficient depth and coverage. In this study we have sequenced and analyzed the genome of a South Asian Indian female (SAIF) from the Indian state of Kerala.
We identified over 3.4 million SNPs in this genome including over 89,873 private variations. Comparison of the SAIF genome with several published personal genomes revealed that this individual shared ~50% of the SNPs with each of these genomes. Analysis of the SAIF mitochondrial genome showed that it was closely related to the U1 haplogroup which has been previously observed in Kerala. We assessed the SAIF genome for SNPs with health and disease consequences and found that the individual was at a higher risk for multiple sclerosis and a few other diseases. In analyzing SNPs that modulate drug response, we found a variation that predicts a favorable response to metformin, a drug used to treat diabetes. SNPs predictive of adverse reaction to warfarin indicated that the SAIF individual is not at risk for bleeding if treated with typical doses of warfarin. In addition, we report the presence of several additional SNPs of medical relevance.
This is the first study to report the complete whole genome sequence of a female from the state of Kerala in India. The availability of this complete genome and variants will further aid studies aimed at understanding genetic diversity, identifying clinically relevant changes and assessing disease burden in the Indian population.
印度拥有超过 13 亿人口,据估计其遗传多样性是欧洲的三倍。下一代测序技术通过实现更快、更低成本的全基因组测序,促进了对多样性的理解。虽然已经对欧洲和亚洲血统的人进行了基因组测序,但直到最近才发布了一份足够深度和覆盖度的来自印度次大陆的男性个体基因组。在这项研究中,我们对一名来自印度喀拉拉邦的南亚印度女性(SAIF)进行了测序和分析。
我们在该基因组中鉴定出超过 340 万个单核苷酸多态性,其中包括超过 89873 个个体变异。将 SAIF 基因组与几个已发表的个人基因组进行比较,发现该个体与每个基因组共享约 50%的 SNPs。对 SAIF 线粒体基因组的分析表明,它与之前在喀拉拉邦观察到的 U1 单倍群密切相关。我们评估了 SAIF 基因组中与健康和疾病后果相关的 SNPs,发现该个体患多发性硬化症和其他几种疾病的风险较高。在分析影响药物反应的 SNPs 时,我们发现了一个变异,预测其对二甲双胍(一种用于治疗糖尿病的药物)有良好的反应。预测华法林不良反应的 SNPs 表明,如果以典型剂量使用华法林,SAIF 个体不会有出血风险。此外,我们还报告了存在一些其他具有医学相关性的 SNPs。
这是第一项报告来自印度喀拉拉邦女性全基因组序列的研究。该完整基因组及其变体的可用性将进一步有助于研究遗传多样性、识别临床相关变化以及评估印度人群中的疾病负担。